US 11,944,849 B2
Systems and methods for combined cosmetic treatment of cellulite with ultrasound
Rainer Pooth, Bad Soden (DE); Harry Frank Abts, Oberursel (DE); Charles D. Emery, Gilbert, AZ (US); and Wojciech Danysz, Nidderau (DE)
Assigned to Ulthera, Inc., Mesa, AZ (US)
Appl. No. 16/970,772
Filed by Ulthera, Inc., Mesa, AZ (US)
PCT Filed Feb. 19, 2019, PCT No. PCT/US2019/018561
§ 371(c)(1), (2) Date Aug. 18, 2020,
PCT Pub. No. WO2019/164836, PCT Pub. Date Aug. 29, 2019.
Claims priority of provisional application 62/632,741, filed on Feb. 20, 2018.
Claims priority of provisional application 62/662,394, filed on Apr. 25, 2018.
Prior Publication US 2021/0093898 A1, Apr. 1, 2021
Int. Cl. A61N 7/02 (2006.01); A61K 41/00 (2020.01); A61N 7/00 (2006.01)
CPC A61N 7/02 (2013.01) [A61K 41/0028 (2013.01); A61N 2007/0008 (2013.01); A61N 2007/0034 (2013.01); A61N 2007/0039 (2013.01)] 20 Claims
OG exemplary drawing
 
10. A method for cosmetically treating gynoid lipodystrophy comprising:
administering to a subject in need thereof an effective amount of HIFU energy and at least one of a dermal filler and a fat-reducing compound,
administering a second treatment 90±10 days later a second HIFU energy and a dermal filler comprising calcium hydroxyapatite and a fat-reducing compound comprising polidocanol, comprising:
focusing the second HIFU energy at a depth 1.5 mm below a skin surface,
wherein the second HIFU therapy is applied at 10 MHz,
wherein the calcium hydroxyapatite is injected in a dermis layer below the skin surface,
wherein the calcium hydroxyapatite is provided in a final concentration of 25-31% w/w,
wherein the polidocanol is injected in a subcutaneous fat below the skin surface, and
wherein the polidocanol is provided in a final concentration of 0.5% w/v.